Bristol-myers Squibb Compnay

Domantis Limited

Philip Drew

Aaron Paul Yamniuk

Suzanne J Suchard

Steven Grant

James William Bryson

James K Tamura

Anish Suri

Steven G Nadler

Olga Ignatovich

Robert P Rehfuss

Laura Price

Steven Sheriff

Stanley Krystek

James Tamura

Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single Vor Vdomain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.

Antibody polypeptides that antagonize CD40L

Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single Vor Vdomain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).

Methods of treating immune diseases by administering antibody polypeptides that antagonize CD40

Nucleic acids encoding antibody polypeptides that antagonize CD40

Methods of treating immune diseases by administering antibody polypeptides that specifically bind CD40L

Antibody polypeptides that antagonize CD40

Nucleic acids encoding antibody polypeptides that antagonize CD40L

Growing community of inventors

Histon, United Kingdom

Philip Drew